Evidence map›Paper›PMID 33458958›Full record

ReviewAdvanced healthcare materials2021

Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.

William Ho, Mingzhu Gao, Fengqiao Li, Zhongyu Li, Xue-Qing Zhang, Xiaoyang Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced healthcare materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

125 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

William HoDepartment of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ, 07102, USA.
Mingzhu GaoEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, P. R. China.
Fengqiao LiDepartment of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ, 07102, USA.
Zhongyu LiDepartment of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ, 07102, USA.
Xue-Qing ZhangEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, and School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, P. R. China.
Xiaoyang XuDepartment of Chemical and Materials Engineering, New Jersey Institute of Technology, Newark, NJ, 07102, USA.ORCID 0000-0002-1634-3329

Funding

American Heart Association 19AIREA34380849Interdisciplinary Program of Shanghai Jiao Tong University ZH2018ZDA36 (19 × 190020006)National Science Foundation 2001606Shanghai Jiao Tong University Scientific and Technological Innovation Funds 2019TPA10
6 · The paper itself

Abstract

Nucleic acid vaccines are a method of immunization aiming to elicit immune responses akin to live attenuated vaccines. In this method, DNA or messenger RNA (mRNA) sequences are delivered to the body to generate proteins, which mimic disease antigens to stimulate the immune response. Advantages of nucleic acid vaccines include stimulation of both cell-mediated and humoral immunity, ease of design, rapid adaptability to changing pathogen strains, and customizable multiantigen vaccines. To combat the SARS-CoV-2 pandemic, and many other diseases, nucleic acid vaccines appear to be a promising method. However, aid is needed in delivering the fragile DNA/mRNA payload. Many delivery strategies have been developed to elicit effective immune stimulation, yet no nucleic acid vaccine has been FDA-approved for human use. Nanoparticles (NPs) are one of the top candidates to mediate successful DNA/mRNA vaccine delivery due to their unique properties, including unlimited possibilities for formulations, protective capacity, simultaneous loading, and delivery potential of multiple DNA/mRNA vaccines. This review will summarize the many varieties of novel NP formulations for DNA and mRNA vaccine delivery as well as give the reader a brief synopsis of NP vaccine clinical trials. Finally, the future perspectives and challenges for NP-mediated nucleic acid vaccines will be explored.

Indexed as

COVID-19NanoparticlesVaccinesDNAHumansRNA, MessengerSARS-CoV-2DNARNA, MessengerVaccinesDNAmRNAnanoparticlesnucleic acidvaccine deliveryvaccines

Identifiers

PMID33458958
PMCPMC7995055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.